Alice Egerton
Overview
Explore the profile of Alice Egerton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knight S, Abbasova L, Zeighami Y, Hansen J, Martins D, Zelaya F, et al.
Biol Psychiatry
. 2025 Feb;
PMID: 39923816
Background: The brain integrates multiple scales of description, from the level of cells and molecules to large-scale networks and behaviour. Understanding relationships across these scales may be fundamental to advancing...
2.
Kelly S, Lame G, Dixon-Woods M, Liberati E, Kyriacou H, Dunn H, et al.
BMJ Open
. 2025 Jan;
14(12):e085827.
PMID: 39806617
Objectives: Suboptimal intrapartum electronic fetal heart rate monitoring using cardiotocography has remained a persistent problem (EFM-CTG). We aimed to identify the range of influences on the safety of using EFM-CTG...
3.
Sun J, Zelaya F, Sendt K, McQueen G, Gillespie A, Lally J, et al.
Schizophrenia (Heidelb)
. 2024 Dec;
10(1):122.
PMID: 39715777
PET and SPECT studies in treatment-resistant schizophrenia (TRS) have revealed significant alterations in regional cerebral blood flow (CBF) during clozapine treatment, which may vary according to the clinical response. Here,...
4.
Gillespie A, Walker E, Hannon E, McQueen G, Sendt K, Avila A, et al.
Transl Psychiatry
. 2024 Sep;
14(1):390.
PMID: 39333502
The second-generation antipsychotic clozapine is used as a medication for treatment-resistant schizophrenia. It has previously been associated with epigenetic changes in pre-clinical rodent models and cross-sectional studies of treatment-resistant schizophrenia....
5.
Livingston N, Kiemes A, Devenyi G, Knight S, Lukow P, Jelen L, et al.
Neuropsychopharmacology
. 2024 Apr;
49(9):1448-1458.
PMID: 38658738
Elevated hippocampal perfusion has been observed in people at clinical high risk for psychosis (CHR-P). Preclinical evidence suggests that hippocampal hyperactivity is central to the pathophysiology of psychosis, and that...
6.
Livingston N, De Micheli A, McCutcheon R, Butler E, Hamdan M, Grace A, et al.
Schizophr Bull
. 2024 Apr;
51(2):446-457.
PMID: 38567823
Background And Hypothesis: Animal models indicate GABAergic dysfunction in the development of psychosis, and that benzodiazepine (BDZ) exposure can prevent the emergence of psychosis-relevant phenotypes. However, whether BDZ exposure influences...
7.
Zahid U, McCutcheon R, Borgan F, Jauhar S, Pepper F, Nour M, et al.
Front Psychiatry
. 2024 Mar;
15:1292075.
PMID: 38495905
[This corrects the article DOI: 10.3389/fpsyt.2022.967941.].
8.
King B, Kempton M, Broberg B, Merritt K, Barker G, Lythgoe D, et al.
Schizophr Res
. 2024 Mar;
266:234-236.
PMID: 38430851
No abstract available.
9.
Griffiths K, Mellado M, Chung R, Lally J, McQueen G, Sendt K, et al.
Brain Behav Immun
. 2023 Oct;
115:223-228.
PMID: 37832895
Background And Hypothesis: Use of clozapine in treatment-resistant schizophrenia is often limited due to risk of adverse effects. Cross-sectional associations between clozapine treatment and low immunoglobulin levels have been reported,...
10.
Griffiths K, Smart S, Barker G, Deakin B, Lawrie S, Lewis S, et al.
Schizophr Res
. 2023 Sep;
260:152-159.
PMID: 37657282
Dysfunction of glutamate neurotransmission has been implicated in the pathophysiology of schizophrenia and may be particularly relevant in severe, treatment-resistant symptoms. The underlying mechanism may involve hypofunction of the NMDA...